Eutilex.Co.Ltd (263050) - Total Assets
Based on the latest financial reports, Eutilex.Co.Ltd (263050) holds total assets worth ₩51.00 Billion KRW (≈ $34.56 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Eutilex.Co.Ltd (263050) net assets for net asset value and shareholders' equity analysis.
Eutilex.Co.Ltd - Total Assets Trend (2016–2024)
This chart illustrates how Eutilex.Co.Ltd's total assets have evolved over time, based on quarterly financial data.
Eutilex.Co.Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Eutilex.Co.Ltd's total assets of ₩51.00 Billion consist of 35.5% current assets and 64.5% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩16.77 Billion | 25.2% |
| Accounts Receivable | ₩2.65 Billion | 4.0% |
| Inventory | ₩321.41 Million | 0.5% |
| Property, Plant & Equipment | ₩35.57 Billion | 53.5% |
| Intangible Assets | ₩884.94 Million | 1.3% |
| Goodwill | ₩1.35 Billion | 2.0% |
Asset Composition Trend (2016–2024)
This chart illustrates how Eutilex.Co.Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see 263050 stock market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Eutilex.Co.Ltd's current assets represent 35.5% of total assets in 2024, a decrease from 59.4% in 2016.
- Cash Position: Cash and equivalents constituted 25.2% of total assets in 2024, down from 57.9% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 3.0% of total assets, unchanged from 3.0% in 2016.
- Asset Diversification: The largest asset category is property, plant & equipment at 53.5% of total assets.
Eutilex.Co.Ltd Competitors by Total Assets
Key competitors of Eutilex.Co.Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Argen-X
F:1AE
|
Germany | €7.18 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
Dashenlin Pharm Grp Co Ltd
SHG:603233
|
China | CN¥26.08 Billion |
|
Staidson Beijing Biopharma
SHE:300204
|
China | CN¥1.26 Billion |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287
|
China | CN¥6.64 Billion |
|
Ardelyx Inc
NASDAQ:ARDX
|
USA | $486.17 Million |
|
Xiangxue Pharmaceutical
SHE:300147
|
China | CN¥7.36 Billion |
Eutilex.Co.Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.65 | 2.29 | 1.68 |
| Quick Ratio | 0.63 | 2.23 | 1.68 |
| Cash Ratio | 0.00 | 1.47 | 0.00 |
| Working Capital | ₩-5.63 Billion | ₩11.53 Billion | ₩28.00 Billion |
Eutilex.Co.Ltd - Advanced Valuation Insights
This section examines the relationship between Eutilex.Co.Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.33 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -8.5% |
| Total Assets | ₩66.51 Billion |
| Market Capitalization | $23.94 Million USD |
Valuation Analysis
Below Book Valuation: The market values Eutilex.Co.Ltd's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Eutilex.Co.Ltd's assets decreased by 8.5% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Eutilex.Co.Ltd (2016–2024)
The table below shows the annual total assets of Eutilex.Co.Ltd from 2016 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ₩66.51 Billion ≈ $45.07 Million |
-8.52% |
| 2023-12-31 | ₩72.70 Billion ≈ $49.27 Million |
-30.40% |
| 2022-12-31 | ₩104.46 Billion ≈ $70.79 Million |
-8.11% |
| 2021-12-31 | ₩113.68 Billion ≈ $77.04 Million |
+7.72% |
| 2020-12-31 | ₩105.54 Billion ≈ $71.52 Million |
+38.85% |
| 2019-12-31 | ₩76.01 Billion ≈ $51.51 Million |
-10.64% |
| 2018-12-31 | ₩85.06 Billion ≈ $57.65 Million |
+45.44% |
| 2017-12-31 | ₩58.49 Billion ≈ $39.64 Million |
+85.38% |
| 2016-12-31 | ₩31.55 Billion ≈ $21.38 Million |
-- |
About Eutilex.Co.Ltd
Eutilex.Co.,Ltd. engages in the discovery and development of immunomodulatory antibody therapeutics to treat cancers and autoimmune diseases. It develops EU101, a fully humanized anti-human 4-1BB monoclonal antibody; EU103, a fully humanized therapeutic monoclonal antibody; and EU501, an 4-1BB mAb-based, tumor antigen targeting bispecific antibodies. The company was founded in 2008 and is headqua… Read more